[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645312":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":40,"responsibleParty":59,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":12,"enrollmentInfo":75,"targetDuration":12,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":89,"whyStopped":12,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Duke University","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational Phase","NO_INTERVENTION","During the first year of enrollment, 50 control group participants will be enrolled in an observational phase and receive usual care only with fluid resuscitation at the discretion of the clinical team. Serum phosphorus levels will be checked every 6 hours and additional blood samples will be collected daily to monitor patients' lab values during their hospital stay.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Treatment Phase","EXPERIMENTAL","During the second year of enrollment, 50 treatment group participants will be enrolled and receive usual care plus continuous sodium phosphate or potassium phosphate (in the case of hypernatremia) which will be delivered by continuous peripheral intravenous infusion at a rate of 30 mmol every 6 hours, as long as serum phosphorus levels are ≤ 4.0 mg\u002FdL. Phosphate infusion will be initiated as soon as possible after patient enrollment and continued for a maximum duration of 72 hours or until patient discharge from the hospital, whichever occurs sooner. Serum phosphorus levels will be checked every 6 hours, and the infusion will be paused until the next recheck if the level rises \\>4.0 mg\u002FdL. Additional blood samples will be collected daily to monitor patients' lab values during their hospital stay.",[18,19],"Drug: Sodium Phosphate","Drug: Potassium Phosphate",[21,26],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":12},"DRUG","Sodium Phosphate","The treatment is administered via continuous peripheral intravenous infusion at a rate of 30 mmol every 6 hours, provided serum phosphorus levels remain at or below 4.0 mg\u002FdL; it begins upon patient enrollment and continues for up to 72 hours.",[14],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":12},"Potassium Phosphate","This treatment will be used in case of hypernatremia. The treatment is administered via continuous peripheral intravenous infusion at a rate of 30 mmol every 6 hours, provided serum phosphorus levels remain at or below 4.0 mg\u002FdL; it begins upon patient enrollment and continues for up to 72 hours.",[14],[31],{"name":32,"affiliation":33,"role":34},"Samuel Francis, MD","Duke University Hospital","PRINCIPAL_INVESTIGATOR",[36],{"name":32,"role":37,"phone":38,"phoneExt":12,"email":39},"CONTACT","919-684-5537","samuel.francis@duke.edu",[41],{"facility":42,"status":12,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Duke University Medical Center","Durham","North Carolina","27710","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-78.89862,35.99403,{"lat":52,"lon":51},[55,58],{"name":56,"role":37,"phone":12,"phoneExt":12,"email":57},"Lezly Collins","lezly.collins@duke.edu",{"name":32,"role":34,"phone":12,"phoneExt":12,"email":12},{"type":60,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[62],{"name":63,"class":64},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100645312","phase-2-phosphate-in-acute-pancreatitis-100645312",false,"NCT07681050","Phosphate in Acute Pancreatitis","Phosphate in Acute Pancreatitis (PPP)","PPP","Inclusion Criteria:\n\n* Age 18 years or older\n* Presenting to the emergency department (ED) with acute pancreatitis meeting 2 or more characteristics of: (1) typical, persistent, severe upper abdominal pain, (2) lipase or amylase levels at least three times greater than the upper limit of normal, and\u002For (3) characteristic findings on abdominal imaging)\n* Trial treatment can be initiated within 24 hours of hospital admission\n* Consent can be obtained from the patient or their legal representative\n\nExclusion Criteria:\n\nContraindications to injectable phosphate including:\n\n* Hyperkalemia\n* Hypercalcemia or significant hypocalcemia\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2) or end-stage renal disease","ALL","18 Years",{"count":76,"type":77},100,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","The goal of this study is to learn if phosphate administration works to treat acute pancreatitis in adults presenting to the emergency department at Duke University Hospital. The main questions it aims to answer are:\n\n* Does having low phosphate levels increase the risk of acute pancreatitis and can giving phosphate through an IV make the illness less severe?\n* Is phosphate therapy practical to use, and what is the appropriate dose?\n* Is this study achievable, and how can the results help design a future randomized controlled trial to assess safety and effectiveness?\n\nParticipants will:\n\n* Receive standard of care or intravenous (IV) phosphate during their hospital stay\n* Have blood samples collected during admission to monitor phosphorus levels\n* Complete follow-up assessments after hospital admission to evaluate how severe the illness is and the effects of phosphate supplementation",[83],"Pancreatitis",[85,83,86,87,88,23,27],"Pancreas","Phosphate","Hypophosphatemia","Hyperphosphatemia","NOT_YET_RECRUITING","2026-06-26",{"date":92,"type":93},"2026-07-02","ACTUAL",{"date":95,"type":77},"2026-07",{"date":97,"type":77},"2029-07",{"name":5,"class":6},1]